Ian Rosbrugh, MD
Urogynecology and Reconstructive Pelvic Surgery · North Kansas City, MONPI 1851456990
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,352 of the $5,315 with a category attached, or 63.1%. 26 manufacturers reported payments, led by Intuitive Surgical at 28.8% of the total. Reporting peaked in 2019 at $2,252 and has fallen 95.2% since, to $107 in 2025.
Across 132 payments — averaging $40.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Axonics, Inc.$928
- Astellas Pharma US Inc$607
- AbbVie$436
- Medtronic$375
- Coloplast$273
- plus $1K from 20 others
What the payments were for
- Travel & lodging$59911%
- Food & beverage$3,35263%
- Education$1,36526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $1,532 |
| Axonics, Inc. | 9 | $928 |
| Astellas Pharma US Inc | 22 | $607 |
| AbbVie(2 entities) | 25 | $436 |
| Medtronic(2 entities) | 8 | $375 |
| Coloplast | 5 | $273 |
| Pfizer | 12 | $168 |
| Caldera Medical, Inc | 3 | $159 |
| Urovant Sciences Inc | 3 | $144 |
| Coopersurgical, Inc. | 1 | $110 |
| Hologic Sales And Service, LLC | 5 | $85 |
| Sumitomo Pharma America, Inc. | 4 | $70 |
| Valencia Technologies Corporation | 3 | $67 |
| Therapeuticsmd, Inc. | 4 | $57 |
| Agile Therapeutics, Inc. | 3 | $49 |
| Merck | 3 | $35 |
| Organon | 2 | $34 |
| Bayer | 2 | $31 |
| Exeltis, USA Inc. | 2 | $31 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Biogen | 1 | $23 |
| Shield Therapeutics Inc | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,362
- Bulkamid$631
- Axonics r-SNM System$631
- Desara$135
- ALTIS$126
- GEMTESA$120
- INTERSTIM ICON$120
- MYRBETRIQ$119
- Paragard$110
How this compares
$5,315 in reported general payments places this provider in the 80th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Missouri.
See all urogynecology and reconstructive pelvic surgery providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 246 | $189,148 |
| GemtesaVibegron | 102 | $70,106 |
| Estradiol | 188 | $14,030 |
| PremarinEstrogens, Conjugated | 23 | $9,718 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 125 | $9,339 |
| Tolterodine Tartrate ErTolterodine Tartrate | 110 | $6,479 |
| YuvafemEstradiol | 23 | $3,036 |
| Trospium Chloride | 58 | $3,036 |
| Solifenacin Succinate | 88 | $2,927 |
| Colestipol Hcl | 36 | $2,032 |
| Methenamine Hippurate | 48 | $1,898 |
| Clobetasol Propionate | 16 | $1,292 |
| Desmopressin Acetate | 20 | $1,009 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $696 |
| Cefdinir | 34 | $613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $607 | $189,148246 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $70 | $70,106102 claims |
| PfizerPremarin | $168 | $9,71823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Missouri.
Other urogynecology and reconstructive pelvic surgery in North Kansas City
- Marlana RayNorth Kansas City$2K
- Elizabeth WilliamsSt. Louis$195K
- Denicia DwaricaColumbia$19K
- Dionysios VeronikisSaint Louis$6K
- Raymond FosterColumbia$6K
- Jerry LowderSaint Louis$4K
- Stephen WassingerKansas City$3K
- Nia JenkinsKansas City$3K
- Richard HillKansas City$3K
- Joe ShiSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.